Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06036004 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus

Study acronym: OxyTUTION
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 2 to 3v5
  2. Eligibility criteria shortened, about 12 wordsv4
  3. Study sites: 1 to 2v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2023 to Jan 8, 2024
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized, placebo-controlled, double-blind trial aims to investigate intranasal OXT as a novel therapeutical option in central diabetes insipidus (cDI) to improve psychological symptoms and socio-emotional functioning. Optionally, patients can present for additional assessments in sub-studies: * fMRI sub-study at day 14 (± 2 days) (one additional visit) * Social-stress sub-study at day 14 (± 2 days) (one additional visit)
Trial Details
NCT Number NCT06036004
Lead Sponsor University Hospital, Basel, Switzerland
Conditions
(from sponsor)		 Central Diabetes Insipidus (cDI)
Related terms Diabetes Insipidus, Diabetes Insipidus, Neurogenic
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov